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AVIDIN AS A MODEL FOR CHARGE DRIVEN TRANSPORT INTO
CARTILAGE: RELEVANCE TO OSTEOARTHRITIS DRUG DELIVERY
A.G. Bajpayee, A.J. Grodzinsky. MIT, Cambridge, MA, USA
Purpose: There is an unmet need for effective ways to locally and safely
introduce DMOADs into cartilage, to minimize systemic adverse effects
and to increase drug speciﬁcity for targets in the tissue. Several studies
have focused on drug-encapsulating polymeric particles whose effec-
tiveness depends on their ability to enter the dense cartilage ECM and to
be retained over time. Our recent studies using solutes having a wide
size range (1-15nm diameter) revealed that nanoparticles with diam-
eter<10nm could penetrate into and diffuse throughout cartilage while
larger solutes became trapped within the superﬁcial zone. We now
conﬁrmed this size limitation using NeutrAvidin, a globular protein
(diamw7nm, 60kDa, electrically neutral). While nanoparticle transport
is size and shape dependent, surface charge can greatly affect their
binding within ECM. Therefore, we compared the binding and transport
properties of NeutrAvidin to Avidin, a highly positively charged protein
of similar MW and size.
Methods: Cartilage disks (6mm diam, 1mm thick) were harvested from
the femoropatellar grooves of 1-2 week old bovine calf knee joints.
Transport and binding properties of FITC-labeled NeutrAvidin (pIw7)
and Avidin (pIw10.5) were measured. A transparent PMMA transport
chamber (Fig 1F) allowed diffusion of solutes from only one side
(superﬁcial zone) of the disk. Half-cylindrical disks were placed within
slots in the middle of the chambers. The chamber side facing the
superﬁcial zone was ﬁlled withw45ml solution of solute in 1X-PBS; the
other side was ﬁlled with 1X PBS. The chamber was placed on a low-
speed rocker inside a 37-deg incubator. At selected times, samples were
removed from the chamber and gently rinsed. A full-thickness slice was
cut from the center of the sample and imaged using a confocal micro-
scope at 10X magniﬁcation. For desorption studies, the solute solution
was removed from the chamber and replaced with 1X or 10X PBS.ĂResults: Figs 1A, B, C along with their ﬂuorescence intensity-vs-depth
graphs show increasing penetration of NeutrAvidin at 1, 2 and 4 days
from the superﬁcial zone (denoted by arrows). Fluorescence intensity is
plotted vs distance from the left edge of the images. Figs. 1D, E show
explants after 24h desorption of NeutrAvidin in 1X and 10X PBS
respectively, suggesting that most NeutrAvidin diffused out similarly by
24h. In contrast, Avidin completely penetrated and diffused throughout
the cartilage within 24h (Fig 2A). While some Avidin diffused out of the
explants after 24h in 1XPBS (Fig 2B), signiﬁcantly more Avidin diffused
out in 10X PBS. Explants within the chamber (Fig. 1F) show visual
evidence of signiﬁcantly higher uptake of Avidin compared to Neu-
trAvidin in 24h (i.e., cartilage ﬂuorescence staining).
Conclusions: Our results suggest that the transport and binding of
Avidin into bovine cartilage is driven by strong electrostatic interac-
tions. Despite their similar sizes, Avidin penetrated through the full
thickness (1mm) of cartilage in 24h, while it took 4 days for NeutrAvidin
to penetrate half the thickness. A 400-times greater uptake was
measured for Avidin compared to NeutrAvidin in 24h. NeutrAvidin
diffused out in both 1X and 10X PBS while Avidin remained bound in 1X
PBS but diffused out in 10X PBS. We hypothesize that Avidin binds to
negatively charged GAG chains in the cartilage: both Avidin and Neu-
trAvidin exhibited identical absorption and desorption properties in
GAG-depleted cartilage explants (data not shown), further conﬁrming
the effects of electrostatic interactions. Using principles of Donnan
equilibrium, we calculated a net charge of approx. +15 on Avidin. This
work suggests that polymeric particles mimicking the structure of
Avidin (i.e.,w7nm diameter with high positive charge) might facilitate
higher and faster uptake into cartilage from the surrounding synovial
ﬂuid, and also bind within the tissue, thereby providing sustained local
drug delivery.567
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Purpose: Osteoarthritis (OA) has been associated with the metabolic
syndrome and is characterized by inﬂammation in joint tissues. Since
statins and ﬁbrates are potentially capable of decreasing inﬂammatory
processes in the joint as well as improving the metabolic proﬁle of
patients, theymight be considered as potential drugs for preventing OA.
To investigate whether OA development in the tibiofemoral joint can be
prevented or delayed by statins and/or ﬁbrates, we orally administered
these drugs in different doses to STR/ORT mice that develop sponta-
neous OA.
Methods: 8 weeks old male STR/Ort mice (n¼72) were divided into 6
experimental groups (n¼12 per group). One group received reference
diet (CTR) and the other groups received reference diet mixed with two
different dosages of simvastatin (40 mg/kg body weight (BW)/day or 80
mg/kg BW/day) or fenoﬁbrate(100 mg/kg BW/day or 200 mg/kg BW/
day) or a combination of simvastatin (40 mg/kg BW/day) and fenoﬁ-
brate (100 mg/kg BW/day). Mice were euthanized after 16 weeks of
treatment at the age of 6 months. Serum measurement of cholesterol
(Chol), triglyceride (TG) and amyloid A (SAA) was performed. Knee
cartilage damage was evaluated by histology using the OARSI scoring
method.
Results: Fenoﬁbrate treated mice gained less BW compared to other
mice. Serum Chol and TG were not signiﬁcantly different between the
groups at 16 weeks. SAAwas increased in the CTR group after 16 weeks.
Simvastatin treatment did not decrease SAA. Fenoﬁbrate treatment
reduced SAA at 16 weeks to the level before start of treatments. Carti-
lage damage was most profound in the medial compartment of the
joint. No signiﬁcant difference in OA score was detected between the
different groups, although a trend to a lower OA score was seen in the
80 mg/kg bodyweight/day simvastatin treated group. No correlation
was found between BW, serum Chol, serum TG, SAA and OA scores.
Conclusions: In our study, statin and ﬁbrate treatment did not signif-
icantly decrease the development of OA cartilage damage in STR/Ort
mice at the age of 6 months. Our results indicate that ﬁbrate treatment
could prevent the increase in BW and SAA. However, BW and SAA are
not correlated with OA cartilage damage in the STR/Ort mice.
